Welcome to our dedicated page for NASDAQ news (Ticker: nasdaq), a resource for investors and traders seeking the latest updates and insights on NASDAQ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NASDAQ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NASDAQ's position in the market.
Atossa Therapeutics (Nasdaq: ATOS) presented four clinical updates at SABCS 2025 on (Z)-endoxifen, covering DCIS active surveillance, low-dose I-SPY2 pilot data, ESR1-mutant mechanistic results, and the Phase 2 EVANGELINE neoadjuvant trial.
Key facts: daily 10 mg (Z)-endoxifen was well tolerated with 95% of patients completing ≥75% therapy; MRI tumor volume median change was -72%; ctDNA clearance occurred in 70% of initially positive patients; EVANGELINE run-in showed 86% with Week 4 Ki-67 ≤10% supporting a 40 mg Phase 2 dose.
1-800-FLOWERS.COM (NASDAQ: FLWS) appointed Alexander Zelikovsky as Chief Information Officer effective Dec 8, 2025. Zelikovsky will report to CEO Adolfo Villagomez and lead enterprise IT applications, data architecture, data management, cybersecurity, business intelligence, and support for AI and digital commerce initiatives.
This hire is positioned to accelerate the company’s digital transformation and omnichannel growth across its portfolio of brands.
Virax Biolabs Group (Nasdaq: VRAX) closed a private placement raising $5.0 million gross proceeds by issuing 12,500,000 ordinary shares (or equivalents) and preferred investment options to buy up to 12,500,000 ordinary shares at a combined price of $0.3999 per pre-funded warrant plus preferred option.
The pre-funded warrants are exercisable immediately at $0.0001 (no expiry). Preferred investment options are exercisable at $0.40 per share for five years from the effective date of a required registration statement. H.C. Wainwright acted as placement agent.
Net proceeds are intended for general working capital and are expected to extend cash runway into H1 2028, beyond planned completion and regulatory submissions for ViraxImmune US PASC study (FDA) and UK PAIS study (MHRA). The company agreed to register the resale of issued securities and to reduce and extend earlier preferred option terms (exercise price from $2.934 to $0.40 and extended term).
Virax Biolabs Group (Nasdaq: VRAX) announced a private placement to raise gross proceeds of approximately $5.0 million through the sale of 12,500,000 ordinary shares (or equivalents) and associated preferred investment options at $0.40 per share. The preferred investment options are exercisable immediately for five years from the effective date of an Initial Registration Statement. Closing is expected on or about December 4, 2025, subject to customary conditions. H.C. Wainwright is the exclusive placement agent. The company said net proceeds will be used for working capital and general corporate purposes. Virax agreed to file and seek effectiveness of a resale registration statement for the issued securities within specified timing and to repricing/extend prior Series A and B preferred options to the same terms.
Virax Biolabs (NASDAQ: VRAX) reported clinical and operational progress and outlined 2026 priorities focused on its ViraxImmune™ T cell diagnostic programme for post-acute infection syndromes (PAIS).
Key facts: full recruitment completed in UK study VRX-002 (160 participants) with initial data expected in Q2 2026; second UK study VRX-003 fully enrolled (100 subjects); U.S. research collaboration with Emory University to support a planned U.S. study; ongoing expansion of the ImmuneSelect RUO product portfolio for near-term research revenue; and a debt-free balance sheet with $3.3M cash, total assets of $5.7M, liabilities of $0.6M and market capitalization of ~$1.7M.
Mammoth Energy Services (NASDAQ: TUSK) announced the sale of its engineering subsidiary Aquawolf to Qualus for an aggregate purchase price of $30.0 million on Dec 2, 2025. Aquawolf's revenue rose from $12.1M in 2022 to $17.3M in 2024, with net income increasing from $1.1M to $1.8M over the same period, and produced $12.0M revenue and $1.3M net income for the nine months ended Sept 30, 2025.
At closing Mammoth received $23.5M cash proceeds; $2.5M was placed in escrow for post-closing adjustments and indemnities through at least Dec 1, 2026. Fifth Third Bank consented and released associated collateral; the company said its borrowing base remains unchanged. Management characterized the sale as part of portfolio optimization and capital deployment to support long-term shareholder value.
Atossa (Nasdaq: ATOS) highlighted a newly published peer‑reviewed hypothesis article and an invited scientific presentation supporting the investigational therapy (Z)-endoxifen for Duchenne muscular dystrophy (DMD) and symptomatic female carriers (D‑CAPs).
The paper maps multi‑pathway mechanisms — ER modulation, PKC‑β1 inhibition, AKT/mTOR and NF‑κB effects — and notes potential advantages over tamoxifen due to more consistent exposure. Atossa plans preclinical validation and fit‑for‑purpose clinical studies focused on safety, PK/PD, functional and cardiac endpoints; a follow‑up manuscript on utrophin modulation is under review.
Atossa Therapeutics (Nasdaq: ATOS) announced four abstracts featuring (Z)-endoxifen research were accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS), Dec 9-12, 2025 in San Antonio, TX. The company will present four posters on Dec 11-12 covering DCIS management, a low-dose I-SPY2 endocrine pilot, ESR1 mutant activity, and a Phase 2 neoadjuvant EVANGELINE trial.
Presentations include scheduled poster sessions on Dec 11 (12:30pm–2:00pm CT) and Dec 12 (7:00am–8:30am CT and 12:30pm–2:00pm CT).
Virax Biolabs (NASDAQ: VRAX) completed full UK recruitment for its multi-centre study of the ViraxImmune™ T cell assay in Post-Acute Infection Syndromes (PAIS), reaching the target of 160 participants in a 3:1 randomised design with 40 symptomatic patients each for Long COVID, PTLD, and ME/CFS. Clinical samples will undergo immunological analysis to evaluate assay performance to support UK regulatory filings with the MHRA and inform potential U.S. submissions.
Virax also received constructive FDA feedback from a Sept 10, 2025 pre-submission meeting and plans a U.S. clinical study with Emory University in 2026. Initial readouts are expected in Q2 2026.
Atossa Therapeutics (Nasdaq: ATOS) highlighted enrollment progress and biomarker strategy for the RECAST™ Phase 2 DCIS platform trial ahead of an Early Detection Research Conference presentation on October 21, 2025.
RECAST is a multi-arm, randomized neoadjuvant trial testing standard endocrine therapy and novel agents—(Z)-Endoxifen, elacestrant, Hav-088—with imaging, biomarker discovery, and quality-of-life endpoints. Enrollment began January 2024 with 50 of 400 patients enrolled across 17 active U.S. sites. The trial aims to identify patients suitable for long-term active surveillance and generate interim imaging and biomarker readouts to de-risk later-stage development.
